Cubist Systematic Strategies’s Viking Therapeutics VKTX Stock Holding History

Cubist Systematic Strategies’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-9,300	Closed	-$225K	–	3557
2025 Q1	$225K	Sell	9,300 -83,600	-90%	-$2.64M	﹤0.01%	2477
2024 Q4	$3.74M	Buy	92,900 +5,600	+6%	+$319K	0.02%	997
2024 Q3	$5.53M	Sell	87,300 -67,800	-44%	-$3.98M	0.03%	770
2024 Q2	$8.22M	Buy	155,100 +25,800	+20%	+$1.69M	0.06%	510
2024 Q1	$10.6M	Buy	+129,300	New	+$5.75M	0.06%	496
2023 Q4	–	Sell	-10,200	Closed	-$113K	–	4151
2023 Q3	$113K	Sell	10,200 -190,800	-95%	-$2.73M	﹤0.01%	2919
2023 Q2	$3.26M	Buy	+201,000	New	+$4.21M	0.02%	1113

Other funds holding VKTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cubist Systematic Strategies's VKTX Position: Q3 2025 in Review

Cubist Systematic Strategies reduced its Viking Therapeutics (VKTX) stake by 89% in Q3 2025, selling an estimated $15.9M and leaving 64,355 shares worth $1.69M. The position accounts for 0.01% of the portfolio, ranked #1663.

Cubist Systematic Strategies first reported a position in VKTX in Q2 2018 and has held it in 18 quarters since. The position peaked at $15.8M in Q2 2025. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

Cubist Systematic Strategies held 64,355 shares of Viking Therapeutics worth $1.69M as of Q3 2025.
Cubist Systematic Strategies sold 532,295 Viking Therapeutics shares in Q3 2025, an estimated $15.9M.
Viking Therapeutics made up 0.01% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1663 holding.
Cubist Systematic Strategies first reported a position in Viking Therapeutics in Q2 2018 and has held it in 18 quarters since.
Cubist Systematic Strategies's Viking Therapeutics position peaked at $15.8M in Q2 2025.
370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.